Experience
Valeant; Salix; Progenics
Mylan Pharmaceuticals, Inc.
Represents Valeant, Salix, and Progenics in Hatch-Waxman patent infringement litigation concerning multiple ANDAs for generic subcutaneous versions of Relistor®. The District of New Jersey granted summary judgment in favor of Valeant, Salix and Progenics on U.S. Patent No. 8,552,025 covering Subcutaneous Relistor® through 2024.
Valeant; Salix; Progenics v. Mylan Pharmaceuticals, Inc., 2:15-cv-08180, 2:17-cv-06714, D.N.J., Judges Chesler, Waldor
Valeant Pharmaceuticals NA, LLC v. Zydus Pharmaceuticals, Inc.
Valeant Pharmaceuticals NA, LLC
Valeant Pharmaceuticals North America, LLC v. Actavis, Inc.
Valeant Pharmaceuticals North America, LLC
Dow Pharmaceutical Sciences, Inc. v. Taro Pharmaceuticals U.S.A., Inc.
Dow Pharmaceutical Sciences, Inc.; Valeant
Valeant Pharmaceuticals International, Inc. v. Mylan Pharmaceuticals Inc.
Valeant Pharmaceuticals International, Inc.
Finnegan secures 10 years of patent protection for Relistor®
Valeant; Salix; Progenics
Dow Pharmaceutical Sciences, Inc. v. Tolmar, Inc.
Dow Pharmaceutical Sciences, Inc.
Elan Pharmaceuticals, Inc. v. Ivax Pharmaceuticals, Inc.
Elan Pharmaceuticals, Inc.
Medicis Pharmaceutical Corp. v. Apotex, Inc.
Medicis Pharmaceutical Corp.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.